Kuljeet S. Gugnani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kuljeet S. Gugnani has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro N. Rondón Ortiz
Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
4 shared publications Timothy J. Maher
Department of Pharmaceutical Sciences, MCPHS University, 179 Longwood Avenue, Boston, MA, USA
4 shared publications- Alejandro J. Pino-Figueroa
MCPHS University 179 Longwood Avenue Boston MA 02115 USA mcphs.edu
2 shared publications Dina H. Dawood
Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries Research Division, National Research Center, 33 El Bohouth St. (former El Tahrir St.), Dokki, Giza, P.O. Box 12622, Egypt
2 shared publicationsMark Böhlke
Department of Pharmaceutical Sciences, MCPHS University, 179 Longwood Avenue, Boston, MA, USA
2 shared publications- Rasha Zakaria Batran
Chemistry of Natural Compounds Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt
2 shared publications
Latest Publications
- 1 July 2021
- Published by Elsevier in Neurochemistry International
- Vol. 147, 105052
Neuroprotective effects of disubstituted dithiolethione ACDT against manganese-induced toxicity in SH-SY5Y cells
- 1 July 2021
- Published by Elsevier in Neurochemistry International
- Vol. 147, 105052
Neuroprotective effects of disubstituted dithiolethione ACDT against manganese-induced toxicity in SH-SY5Y cells
- Open Access
- 1 February 2018
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 340, 67-76
Neuroprotective activity of macamides on manganese-induced mitochondrial disruption in U-87 MG glioblastoma cells
- 1 February 2018
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 340, 67-76
Open AccessNeuroprotective activity of macamides on manganese-induced mitochondrial disruption in U-87 MG glioblastoma cells
- 1 December 2017
- Published by Elsevier in Bioorganic Chemistry
- Vol. 75, 274-290
Coumarinyl pyranopyrimidines as new neuropeptide S receptor antagonists; design, synthesis, homology and molecular docking
- 1 December 2017
- Published by Elsevier in Bioorganic Chemistry
- Vol. 75, 274-290
Coumarinyl pyranopyrimidines as new neuropeptide S receptor antagonists; design, synthesis, homology and molecular docking
- Open Access
- 14 November 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 772
High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells
Low-density lipoprotein receptor-related protein 1 (LRP1) is an endocytic receptor involved in the uptake of a variety of molecules, such as apoE, α2-macroglobulin, and the amyloid β peptide (Aβ), for either transcellular transport, protein trafficking or lysosomal degradation. The LRP1 gene can be transcribed upon activation of peroxisome proliferator receptor activated-γ (PPARγ) by the potent PPARγ agonist, rosiglitazone (RGZ). In previous studies, RGZ was shown to upregulate LRP1 levels in concentrations between 0.1 and 5 μM in HepG2 cells. In this study, we sought to replicate previous studies and to investigate the molecular mechanism by which high concentrations of RGZ reduce LRP1 levels in HepG2 cells. Our data confirmed that transcriptional activation of LRP1 occurred in response to RGZ at 3 and 10 μM, in agreement with the study reported by Moon et al. (2012a). On the other hand, we found that high concentrations of RGZ decreased both mRNA and protein levels of LRP1. Mechanistically, transcriptional dysregulation of LRP1 was affected by the downregulation of PPARγ in a time- and concentration-dependent manner. However, downregulation of PPARγ was responsible for only 40% of the LRP1 reduction and thereby the remaining loss of LRP1 (60%) was found to be through degradation in the lysosomal system. In conclusion, our findings demonstrate the mechanisms by which high concentrations of RGZ caused LRP1 levels to be reduced in HepG2 cells. Taken together, this data will be helpful to better explain the pharmacological modulation of this pivotal membrane receptor by PPARγ agonists.
- 14 November 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 772
Open AccessHigh Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells
Low-density lipoprotein receptor-related protein 1 (LRP1) is an endocytic receptor involved in the uptake of a variety of molecules, such as apoE, α2-macroglobulin, and the amyloid β peptide (Aβ), for either transcellular transport, protein trafficking or lysosomal degradation. The LRP1 gene can be transcribed upon activation of peroxisome proliferator receptor activated-γ (PPARγ) by the potent PPARγ agonist, rosiglitazone (RGZ). In previous studies, RGZ was shown to upregulate LRP1 levels in concentrations between 0.1 and 5 μM in HepG2 cells. In this study, we sought to replicate previous studies and to investigate the molecular mechanism by which high concentrations of RGZ reduce LRP1 levels in HepG2 cells. Our data confirmed that transcriptional activation of LRP1 occurred in response to RGZ at 3 and 10 μM, in agreement with the study reported by Moon et al. (2012a). On the other hand, we found that high concentrations of RGZ decreased both mRNA and protein levels of LRP1. Mechanistically, transcriptional dysregulation of LRP1 was affected by the downregulation of PPARγ in a time- and concentration-dependent manner. However, downregulation of PPARγ was responsible for only 40% of the LRP1 reduction and thereby the remaining loss of LRP1 (60%) was found to be through degradation in the lysosomal system. In conclusion, our findings demonstrate the mechanisms by which high concentrations of RGZ caused LRP1 levels to be reduced in HepG2 cells. Taken together, this data will be helpful to better explain the pharmacological modulation of this pivotal membrane receptor by PPARγ agonists.
- 8 August 2017
- Published by Wiley in Archiv der Pharmazie
- Vol. 350 (9)
New Coumarin Derivatives as Anti‐Breast and Anti‐Cervical Cancer Agents Targeting VEGFR‐2 and p38α MAPK
Breast and cervical cancers are the most common gender‐specific cancers affecting women worldwide. In this investigation, we highlighted the synthesis, VEGFR‐2 and p38α MAPK inhibitory activity of new series of fluorinated coumarin‐based derivatives featuring a variety of bioactive chemical moieties attached or fused to the coumarin nucleus at the 3 and/or 4 position. The bioactive inhibitors were further assessed for their anti‐proliferative effect against human MCF‐7 breast cancer and HeLa cervical cancer cell lines, respectively. Most of the tested compounds showed potent preferential inhibition effects against human VEGFR‐2 and remarkable anticancer activities in the human breast cancer cell line MCF‐7. Compounds 29, 24, and 2 displayed the highest inhibitory activity against VEGFR‐2 (94% inhibition) and they were the most potent anticancer agents toward MCF‐7 cancer cells with IC50 values of 7.90, 8.28, and 8.30 μg/mL, respectively. Compound 13 inhibited p38α MAPK phosphorylation with a significant reduction in % cell viability against HeLa cancer cells at 10 and 30 µM. Docking experiments carried out on VEGFR‐2 and p38 MAPK crystallographic structures revealed that the active compounds bind to the active sites through H‐bonds, arene–cation, and hydrophobic π–π interactions. QSAR analysis demonstrated considerable correlation coefficient (R2 = 0.76969) and root mean square error (RMSE = 0.10446) values. Also, the residual values between the experimental pIC50 and predicted pIC50 are very close, indicating the reliability of the established QSAR model.
- 8 August 2017
- Published by Wiley in Archiv der Pharmazie
- Vol. 350 (9)
New Coumarin Derivatives as Anti‐Breast and Anti‐Cervical Cancer Agents Targeting VEGFR‐2 and p38α MAPK
Breast and cervical cancers are the most common gender‐specific cancers affecting women worldwide. In this investigation, we highlighted the synthesis, VEGFR‐2 and p38α MAPK inhibitory activity of new series of fluorinated coumarin‐based derivatives featuring a variety of bioactive chemical moieties attached or fused to the coumarin nucleus at the 3 and/or 4 position. The bioactive inhibitors were further assessed for their anti‐proliferative effect against human MCF‐7 breast cancer and HeLa cervical cancer cell lines, respectively. Most of the tested compounds showed potent preferential inhibition effects against human VEGFR‐2 and remarkable anticancer activities in the human breast cancer cell line MCF‐7. Compounds 29, 24, and 2 displayed the highest inhibitory activity against VEGFR‐2 (94% inhibition) and they were the most potent anticancer agents toward MCF‐7 cancer cells with IC50 values of 7.90, 8.28, and 8.30 μg/mL, respectively. Compound 13 inhibited p38α MAPK phosphorylation with a significant reduction in % cell viability against HeLa cancer cells at 10 and 30 µM. Docking experiments carried out on VEGFR‐2 and p38 MAPK crystallographic structures revealed that the active compounds bind to the active sites through H‐bonds, arene–cation, and hydrophobic π–π interactions. QSAR analysis demonstrated considerable correlation coefficient (R2 = 0.76969) and root mean square error (RMSE = 0.10446) values. Also, the residual values between the experimental pIC50 and predicted pIC50 are very close, indicating the reliability of the established QSAR model.
- Open Access
- 1 January 2017
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 9 (8) , 1028-1046
Influence of iron metabolism on manganese transport and toxicity
The structural and chemical similarities between manganese (Mn) and iron (Fe) allow the two metals to interact with each other in biological systems.
- 1 January 2017
- Published by Oxford University Press (OUP) in Metallomics
- Vol. 9 (8) , 1028-1046
Open AccessInfluence of iron metabolism on manganese transport and toxicity
The structural and chemical similarities between manganese (Mn) and iron (Fe) allow the two metals to interact with each other in biological systems.